Everolimus and long-term outcomes in renal transplantation

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F11%3A00002470" target="_blank" >RIV/00023001:_____/11:00002470 - isvavai.cz</a>
Result on the web
<a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1399-0012.2009.01093.x/abstract;jsessionid=5A2AFFCBCD334A06623525E356F8D845.d02t04" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/j.1399-0012.2009.01093.x/abstract;jsessionid=5A2AFFCBCD334A06623525E356F8D845.d02t04</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/j.1399-0012.2009.01093.x" target="_blank" >10.1111/j.1399-0012.2009.01093.x</a>

Result language
angličtina
Original language name
Everolimus and long-term outcomes in renal transplantation
Original language description
A series of recent meetings brought together experts in the field of transplantation to discuss the challenge of improving long-term outcomes and establishing optimal strategies for immunosuppression after renal transplant. This supplement is a summary of these meetings, the objectives of which were to present the supporting data and rationale for using the mammalian target of rapamycin inhibitor (mTORi) everolimus as a part of a preemptive strategy to improve long-term outcomes, and to discuss practical aspects and proposed algorithms for preemptive use of everolimus.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FJ - Surgery including transplantology
OECD FORD branch
—

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)